Semaglutide Weight Loss
Prescription Online

Semaglutide is a GLP-1 receptor agonist that mimics the hormone GLP-1, which is released after eating. It slows gastric emptying, reduces appetite signals in the brain, and helps regulate blood sugar. Clinical trials show patients lose an average of 15–17% of body weight over 68 weeks.

Compounded semaglutide is a compounded medication prepared by a licensed pharmacy for an individual patient when clinically appropriate. It is not FDA-approved as a finished drug product and is not the same as or interchangeable with any FDA-approved semaglutide product. Open Water Rx prescribes compounded semaglutide through licensed, FDA-registered compounding pharmacy partners only when an independent licensed medical provider determines it is clinically appropriate for the individual patient.

Compounded semaglutide is prescribed when an independent licensed medical provider determines it is clinically appropriate for the individual patient, for example, when a patient requires a specific dosage strength, formulation, or delivery method not available in the commercially manufactured product, or when the patient has a documented clinical need that the commercial product cannot meet.

Compounding is not offered simply as a lower-cost alternative to commercially available GLP-1 products. Under FDA regulations, compounding is only legally permissible when there is a valid individual clinical reason. Your prescribing provider makes this determination independently, based solely on your health profile.

Compounded semaglutide is not FDA-approved. It is prepared by independent, FDA-registered compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Open Water Rx does not manufacture, compound, or dispense medications.

Most patients notice reduced appetite within the first 1–2 weeks. Meaningful weight loss typically begins within 4–8 weeks. Individual results vary and are not guaranteed. Clinical response is typically assessed at 12–16 weeks as dosage is gradually adjusted by your provider to your appropriate therapeutic level.

The most common side effects are gastrointestinal: nausea, mild stomach discomfort, and occasional constipation, especially during dose escalation. These typically subside as your body adjusts.

Important safety information: GLP-1 receptor agonists, including semaglutide, cause thyroid C-cell tumors in rodents. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Semaglutide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis has been reported in patients treated with GLP-1 receptor agonists. Discontinue semaglutide promptly if pancreatitis is suspected and do not restart if confirmed. Semaglutide is not recommended in patients with a history of pancreatitis.

Your licensed medical provider will review all relevant risks and benefits with you before prescribing. This is not a complete list of side effects.

In most cases, no. Open Water Rx is telehealth. You complete a health evaluation online, a licensed medical provider reviews it, and your semaglutide prescription ships directly to your door. Some states require a synchronous initial visit. Availability varies by state.

Semaglutide plans start at $249/month and tirzepatide plans start at $339/month. One monthly price includes provider review, medication (if prescribed), shipping (if prescribed), and ongoing support. Some longer-term prepaid plans may lower the effective monthly rate. Pricing and availability are subject to clinical appropriateness and regulatory change.